학술논문
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, July 2022, 23(7):851-864)
Subject
Language
English
ISSN
14745488
14702045
14702045